JUN 17, 2015 08:00 AM PDT

Real-Time Profiling of Tumor Heterogeneity in Metastatic Disease

SPONSORED BY: Epic Sciences, Epic Sciences
Speakers
  • VP of Translational Research, Epic Sciences
    Biography
      Mark Landers has 20 years of experience developing and commercializing molecular assays to drive translational and clinical research. In his current position as VP of Translational Research at Epic Sciences, he is leading the development of assay's to characterize CTC by genotype and phenotype at the single cell level. These assays can be utilized to develop clinical tests to drive patient care decisions. Prior to his tenure at Epic Sciences, Mark was Head of R&D at AltheaDx where he developed several companion assays for targeted therapies. He has also held several senior level scientist positions in the San Diego biotech community, at companies including LifeTechnologies, Ceregene and Vical.

    Abstract:
    DATE: June 17th, 2015
    TIME: 8am Pacific time, 11am Eastern time

    Spatial heterogeneity of tumors has been identified within and between metastatic lesions and can be visualized with targeted PET imaging, biopsy IHC and microdissected-targeted NGS. Tissue biopsies can underestimate clonal and phenotypic differences between metastatic sites, and lack of single cell characterization can homogenize intra-tumoral heterogeneity. Additionally, acquired therapeutic resistance leads to temporal heterogeneity of tumors leading to the need for longitudinal tissue biopsies in some patients. Recently, large investments into liquid biopsies have employed the utilization of cfDNA to identify tumor mutations with known targets or are correlated with resistance to disease. However, utilization of cfDNA as a primary tool can underestimate intra-patient tumor heterogeneity and neglect the protein drivers of disease progression, including tyrosine kinase receptor amplification, loss of tumor suppressor function, epithelial plasticity. At Epic Sciences, we have developed a platform to characterize single circulating tumor cells (CTCs) for morphologic, protein and genomic targets at the single cell level and have applied the platform to thousands of samples from metastatic cancer patients. We will present data on the impact of morphology, protein chemistry and genomics of single CTCs in the context of contemporary unmet clinical needs in mCRPC. The impact of this clinical data suggests employment of a rational development of combination therapies to combat disease heterogeneity.

    Show Resources
    You May Also Like
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 02, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 02, 2018 08:00 AM PDT
    Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
    Loading Comments...